Paliperidone, sold under the brand name Invega sustenna among others, is an atypical antipsychotic. It is marketed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing. Paliperidone is mainly used to treat schizophrenia and schizoaffective disorder. Paliperidone palmitate is a long-acting injectable formulation of paliperidone palmitoyl ester indicated for once-every 28 days injection after an initial titration period.
A patient on paliperidone shared his side-effects in a review, " I was on a shot for Schizoaffective Disorder, I've been on this drug Invega Sustenna for the last 5 years. I've gained 65 lbs, I'm 5'4" tall. I'm restless, have liver problems, memory problems. I don't know which symptoms it is treating. I do not hallucinate. I originally got diagnosed with bipolar disorder 23 years ago, because I could not sleep at night. This drug is horrible and there are no benefits from it.”